ArticleTherapeutic advances in psychopharmacology2026
Healthcare resource savings from administering paliperidone palmitate once every 3 months instead of once every month for schizophrenia: a 12-month mirror-image analysis of real-world population-based data.
Article in Therapeutic advances in psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inadequate adherence to antipsychotic medication remains a major driver of relapse, hospitalization, and chronic disease progression in schizophrenia. Long-acting injectable (LAI) antipsychotics may reduce healthcare costs and the risk of relapse. However, evidence regarding the switch from paliperidone palmitate once every month (PP1M) to paliperidone palmitate once every 3 months (PP3M) remains limited. Objectives: To examine the utilization of LAI antipsychotics and investigate the effect of transitioning from PP1M to PP3M on adherence and healthcare utilization. Design: This retrospective, 12-month mirror-image study used nationwide, population-based data from Taiwan to examine changes in healthcare resource utilization and costs after the transition from PP1M to PP3M. Methods: Individuals with schizophrenia who were newly prescribed PP3M after receiving PP1M for at least 12 months between 2016 and 2021 were included. Healthcare resource utilization and costs during the 12 months before PP3M initiation were compared with those during the 12 months after initiation. Risk factors for an unsuccessful transition from PP1M to PP3M were also identified. Results: Among the 4001 patients with schizophrenia spectrum disorders included in this study, 2790 (69.7%) continued PP3M treatment. A younger age, residence in suburban or rural areas, lower concomitant use of other antipsychotics, and higher use of benzodiazepine were independent risk factors for an unsuccessful transition. At 12 months after PP3M initiation, hospitalization costs decreased from NT$38,469.0 to NT$20,062.8 and emergency room visit costs from NT$692.1 to NT$360.9 (both Conclusion: Transitioning from PP1M to PP3M for schizophrenia treatment can significantly reduce healthcare resource utilization and costs. Notably, hospitalization and emergency room visit costs were reduced by approximately half.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.